So far, the BCMA-targeted CAR has shown early success in four Australian multiple myeloma patients in a Phase I trial.

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung ...

A research team has developed a new RNA-based system that can detect coronavirus infection in real time inside living cells—and even trigger antiviral responses only when infection occurs.

The limits of conventional bathing water monitoring are becoming harder to ignore.Many of these sites sit close to treated ...

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...

In an era where precision medicine is redefining patient outcomes, cell separation technologies—encompassing the isolation of ...

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...

Antigen-driven TCR signaling in the epidermis during CD8+ TRM differentiation results in a lower TGFβ requirement for persistence and increased proliferative capacity that together enhance epidermal ...

One of the most striking breakthroughs of Belarusian medicine in the field of oncology is CAR‑T‑cell therapy. 85 people have already ...